PUBBLICATO IL NUOVO NUMERO DELLA WHO PHARMACEUTICAL NEWSLETTER

Fonte: WHO. N 2, aprile 2018

E' disponibile il nuovo numero della WHO Pharmaceutical newsletter.

In questo numero:

REGULATORY MATTERS
• Antihistamines (first generation, oral sedating)
• Clarithromycin
• Clopidogrel and selexipag interaction
• Daclizumab beta
• Dipeptidylpeptidase-4 inhibitors
• Efavirenz
• Flupirtine
• Gadolinium-containing contrast agents
• Hydroxyethyl-starch solution
• Iohexol, Iomeprol
• Kampo medicines containing Gardenia fruit
• Miconazole and warfarin interaction
• Mycophenolate mofetil, mycophenolic acid
• Radium-223 dichloride
• Retinoids
• Sterile talc
• Tolvaptan

SAFETY OF MEDICINE
• Artemisia annua extract in grape seed oil
• Aspirin in chloroform
• Clozapine
• Dabigatran
• Direct-acting antivirals (DAAs)
• Eribulin
• Idarucizumab
• Ruxolitinib
• Sodium-glucose Cotransporter-2 (SGLT2) inhibitors
• Suvorexant
• Ulipristal acetate

SIGNAL
• Artemether/Lumefantrine and Stevens-Johnson syndrome: a recommendation for continued vigilance in malaria-endemic areas
• Quetiapine and valproic acid interactions: signal strengthening

FEATURE
• Enhancing Pharmacovigilance in Low and Middle Income Countries using Smart Safety Surveillance